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This study aimed at determining if synovial cell cultures from rheumatoid arthritis (RA), osteoarthritis (OA), and healthy controls
(HC) diﬀer and are suitable disease models in pharmacological studies, and tested their response to some anti-inflammatory drugs.
Synovial cells were isolated from synovial membrane or joint fluid. Cells were cultivated and exposed to no or TNF-α stimulation
without, or in the presence of, betamethasone, ibuprofen, or a standardized ginger extract. Concentrations of a panel of cytokines,
growth factors, and chemokines were mapped for each culture and condition. Our cells secreted an increased amount of the
cytokines IL-1β, IL-6, and IL-8 in response to TNF-α stimulation in all conditions. OA cells showed a higher IL-6 and IL-8 and
a lower IL-1β production, when not stimulated, than RA and HC cells, which were similar. TNF-α stimulation caused similar
IL-1β, IL-6, and IL-8 release in all groups. Ibuprofen showed no eﬀect on cytokine production, while ginger extract was similar
to betamethasone. Ginger extract was as eﬀective an anti-inflammatory agent as betamethasone in this in vitro model. Cultured
fibroblast-like synoviocytes from OA and RA subjects promise to be a useful pharmacological disease model, but further studies,
to support results from such a model are needed.
1. Introduction
Rheumatoid arthritis (RA) is considered a systemic disease
with a variety of determinants for its pathogenesis, including
T-cell and B-cell dependent pathways [1]. Inflammatory
and autoimmune processes interact with nonimmune cell
types, resulting in cartilage and bone attack [2]. The find-
ing that fibroblast-like synoviocytes from RA patients can
invade cartilage and destruct it, and that these synoviocytes
maintain these characteristics over a period of time in an
in vivo animal experiment in the absence of T-cells [3]
indicates an involvement of fibroblast-like synoviocytes in
the inflammatory response in RA. The possible activation
of fibroblast-like synoviocytes in patients with osteoarthritis
(OA) has been far less considered. It is believed that
the balance between anabolic and catabolic processes in
healthy cartilage is driven by cytokines, and an excess of
proinflammatory cytokines is thought to result in many of
the clinical manifestations of OA [4]. The expression of some
cytokines andmatrix-degrading enzymes has been compared
between cultured fibroblast-like synoviocytes from RA and
OA, showing far more proliferation and cytokine production
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in RA [5]. Demonstration and rating of some cytokines
and mononuclear cell infiltrates by immunohistochemistry
examination of synovial membrane biopsies from RA and
OA patients have shown higher concentrations in RA,
although all the cytokines looked for were present in both
groups [6].
The cells present in the synovial membrane were first
classified as types “A” and “B” [7] and later described
as macrophage-like synoviocytes (type A lining cells) and
fibroblast-like synoviocytes (type B lining cells), respectively
[8]. The synovial membrane has also endothelial cells which
line the lumina of blood vessels and interact with immune
cells in the blood, mainly leukocytes, resulting in extravasa-
tion of these cells, and this is important in the pathogenesis
of inflammatory disorders [9]. All of these four cell types
respond to cytokines and produce cytokines themselves. It
has been stated that molecular and functional characteristics
of cultures of adherent, mostly, fibroblast-like synoviocytes
can provide evidence for pathogenic mechanisms [10];
hence these characteristics are conserved under in vitro
culture.
We have considered if it was possible to establish an
in vitro model of the synovial membrane and cavity for
studies on the conversion of prodrugs intended for topical
administration into the joint to the pharmacologically active
substance. For simplicity and feasibility, this model was
made up from adherent cells cultured from synovial fluid
or synovial membrane biopsies, and thus devoid of T-
and B-cells, and consequently with absence of important
interactions that occur in vivo. Other objectives were to
identify products from the synovial cells contributing to the
inflammation, which may be used as markers of OA and RA
and possibly distinguishing these diseases, and to identify
combined profiles of cytokines characteristics of OA or RA
as compared to a constitutional production by cells from
noninflamed tissue.
The aim of the present study was therefore, by mapping
the concentrations of a panel of cytokines and chemokines,
with no stimulation and after stimulation with tumour
necrosis factor α (TNF-α), to see if the cell cultures diﬀer
between diagnosis of the donor and diﬀer compared to
healthy control cells, and if the treatments with betametha-
sone, ibuprofen, and a standardized extract of the herbs
Zingiber oﬃcinale and Alpinia galanga, with known anti-
inflammatory substances, show any diﬀerences in cell reac-
tions.
2. Materials andMethods
2.1. Ethics. The study was accepted by Copenhagen and
Frederiksberg Municipalities Ethics Committee (Protocol:
Metabonomics-KF-01255092).
2.2. Samples. Samples were taken from OA and RA patients,
as well as from healthy controls. The OA and RA diagnoses
of the included patients were according to the ACR criteria
[11–13].
The samples of synovial fluid were aspirated from the
joint cavity under ultrasound echography guidance, and
the synovial membrane specimens from OA or RA
patients, approximately 5 g, were taken in connection with
orthopaedic surgery.
The samples from healthy controls (HC) were biopsies
of the synovial membrane, five specimens of approximately
10mm3 each, taken from the knee with forceps through an
endoscope, from subjects who had one knee endoscopically
examined for meniscus injury and had consented to have
biopsies taken from the opposite knee, which had given no
symptoms of inflammation like pain or malfunction. None
of these healthy controls had any pre-history of, or showed
any sign of, arthritis.
2.3. Isolation and Cultivation of Synovial Cell. Synovial cells
were isolated from either biopsies of synovial membrane
or samples of joint fluid. Tissue biopsies were minced into
pieces with a length of 3mm along their longest axis. The
amount of joint fluid that had been taken, ranging from
0.5 to 50mL, was centrifuged at RCF 500×g at 20◦C, and
the sediment was transferred to a T-25 tissue culture flask
containing DMEM/high glucose reduced serum (HyClone,
Cat No. SH30565, Thermo Scientific) with 8% Fetalclone
III foetal bovine serum (FBS) (HyClone, Cat No. SH30109,
Thermo Scientific), penicillin 60 i.u./mL, and streptomycin
60 μg/mL. The flasks were placed in a humidified atmosphere
with 5% carbon dioxide at 37◦C, and the medium was
entirely replaced with fresh medium with intervals of seven
days. The adherent cells were harvested after detachment
with trypsin and EDTA when the culture had reached 75%
confluence, frozen-in in FBS with 10% dimethylsulfoxide at
a cooling rate of 1◦C/min, and stored in liquid nitrogen.
For the experiments, cryopreserved cell isolates which
had been passed 1 or 2 times before they were frozen
were selected. These cryo-preserved cell isolates were rapidly
thawed and gently mixed with the previously mentioned
medium, grown to 75% confluence, detached, split, replated,
and again grown until a minimum of 150 cm2 flask bottom
area was covered with a 90% confluent layer of cells with
good fibroblast morphology, corresponding to minimum
1.5×107 cells. This propagation required four to six passages
and at the same time secured total wash-out of any drugs
used by the patients.
A sample from the medium, conditioned through three
days’ culture, was subjected to an RNA hybridization assay,
which is able to demonstrate infection with any of the eight
Mycoplasma species accounting for approximately 95 percent
of all instances of Mycoplasma contamination (MycoProbe,
R&D Systems, Minneapolis, MN, USA). All cell cultures used
for the experiments in the present study were tested negative
for Mycoplasma contamination, like by far most cell cultures
tested routinely in our laboratory.
The cells in the cell culture flasks used for multiplication
of a given cell isolate were detached with Dulbecco’s phos-
phate buﬀered saline (DPBS) containing 1% bovine serum
albumin (BSA) and 2mM EDTA by standing at 4◦C for 10
minutes and occasional knocking.
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2.4. Presentation of the Synovial Model. The practical pre-
sentation of the synovial model was as follows: cells grown
adherent to the bottom of cell culture plates, each plate
divided into eight square fields with an area of 8.6 cm2 each,
and two rows by four columns (Nunc, Cat No. 176600,
Denmark). For each cell population were used a minimum
of three rows by four fields each, in 14 experiments six rows
and in five experiments nine rows. The rows were designated
“A,” “B,” and “C,” respectively. One field in each row was
used for the control treatment with no pharmacologically
active substance added, and the other three fields were
used for treatment with anti-inflammatory substances, to be
reported separately. The suspension of cells that had been
multiplied and harvested was centrifuged at RCF 300×g for
10 minutes. Then the cell precipitate was resuspended in
DMEM/high glucose reduced serum with 3% FBS, penicillin
60 i.u./mL, and streptomycin 60 μg/mL, 1.0mL per field.
The cell population concerned was intended for plus 1.0mL
excess. To each field of the eight-field plates was first pipetted
1.0mL DMEM/high glucose reduced serum with 3% FBS,
followed by 1.0mL of the cell suspension. This favoured
a uniform distribution. The cell culture plates were placed
in humidified atmosphere with 5% carbon dioxide at 37◦C
for two hours, then the medium was replaced with 2.0mL
medium per field, and the plates were incubated.
2.5. Analysis of Composition of Cell Populations Used. The
composition of each cell population, dispensed into eight-
well cell-culture plates, and used for a substance exposure
experiment, was characterised in connection with the plat-
ing. The suspensions of harvested cells from several flasks
were pooled, centrifuged at RCF 300×g for 10 minutes, the
supernatant was aspirated, and the cells were resuspended
in 5mL DPBS with 1% BSA. Aliquots at 50 μL each were
distributed to ten tubes, and these separate aliquots of
the cells were stained with antibodies to CD14, which is
expressed on macrophages including macrophage-like syn-
oviocytes (clone M5E2, RPE-conjugated, BD Biosciences
Pharmingen, San Diego, CA, USA), with CD31, which
is expressed on endothelial cells, macrophages, and some
cells that were unlikely to be present (clone WM59, RPE-
conjugated, BioLegend, San Diego, CA, USA), or with CD90,
also called Thy1, which is expressed on fibroblasts including
fibroblast-like synovial cells at least from the subintimal
region of the synovial membrane [14], activated endothelial
cells, and some cells that were unlikely to be present, and,
importantly, CD90 is not expressed on macrophages (clone
5E10, APC-conjugated, BD Biosciences Pharmingen, San
Diego, CA, USA). To three other aliquots of the cells were
added mouse IgG of the same isotype as the antigen-specific
antibody and conjugated with the same fluorochrome (from
BioLegend, San Diego, CA, USA), to serve as isotype-
matched control cells in the subsequent analysis by flow
cytometry. One aliquot of cells was stained with anti-CD90
and then fixed with 1% formaldehyde, permeabilized with
0.027% saponine, and then stained with antibodies to CD68,
which is expressed in cytoplasmic granules of macrophages,
and in some cells that were unlikely to be present, but not
expressed in fibroblasts (clone Y1/82A, RPE -conjugated,
BD Biosciences Pharmingen, San Diego, CA, USA), and
another tube of fixed and permeabilized cells was labelled
with isotype- and fluorochrome-matched antibodies to the
anti-CD68 and anti-CD90 used. One tube of cells was left
unstained, and one tube was fixed with formaldehyde but
not stained, for use as unstained control for anti-CD68. All
labelings of cells with the fluorochrome-conjugated antibod-
ies were done in DPBS with 1% BSA, with formaldehyde
or saponine added when staining with anti-CD68, standing
at 4◦C for 40 minutes. The concentrations used were those
recommended by the manufacturer. The antibody-stained
cells were washed once, resuspended in 90 μL DPBS with
1% BSA, transferred to microplate wells, and analyzed in a
FACSArray Bioanalyzer flow cytometer (Becton Dickinson
Immunocytometry Systems, San Jose´, CA, USA). In the anal-
ysis of data, the gate for cells counted “positive” according to
a marker was set on the isotype control histogram, referring
to a marker concerned to include no or a few cells, maximum
3%, after which the number and median fluorescence
intensity (MFI) of the marker-positive cells in this gate were
recorded.
2.6. Test Substances. Three test substances or preparations
were chosen, aiming at representing a range of pharmacolog-
ical mechanisms of action: betamethasone, ibuprofen, and
an extract designated “EV.EXT77” (Ferrosan, Denmark) that
had been produced by extraction of the rhizomes of the herbs
Zingiber oﬃcinale and Alpinia galanga, both of which belong
to the ginger family. The extract EV.EXT77 is standardized as
to its concentration of anti-inflammatory substances.
Betamethasone has several mechanisms of action; a
recent review deals with gene regulation by glucocorticoids
[15]. Major mechanisms are inhibition of transcription
factors AP-1 and NF-κB, which in noninflamed conditions
activate the genes for cyclooxygenase-2 (COX-2), some
cytokines, and inducible NO synthase (iNOS). COX-2 (and
its isoenzyme COX-1) increases the production of prostan-
oids (prostaglandins, thromboxanes, and prostacyclins, all
of which have type members that mediate the inflamma-
tory process), resulting in reduced inflammation. Another
major mechanism is modification of basic and induced
transcription of genes for collagenase. Hence the eﬀects
of betamethasone are reduced production of prostanoids
due to the reduced COX-2-expression, reduced production
of the proinflammatory cytokines and chemokines, and
reduced production of iNOS. Ibuprofen is a nonsteroidal
anti-inflammatory drug (NSAID) [16] and is a nonselective
inhibitor of both isoenzymes COX-1 and COX-2, which
catalyze the production of prostaglandins and thrombox-
anes. COX-2 is almost exclusively expressed on sites of
inflammation; hence the action of ibuprofen appears as a
reduced intensity of the inflammatory process. In addition,
ibuprofen inhibits the enzyme 5-lipoxygenase (LOX) at the
concentration used in our study [17]. LOX catalyzes the
synthesis of leukotrienes from arachidonic acid, which is
also the starting substance for the synthesis of prostaglandins
and thromboxanes. Leukotrienes are important mediators
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in inflammatory processes. Ibuprofen also inhibits the
bradykinin and histamine inflammatory pathways [18].
The known anti-inflammatory substances in ginger are
gingerols, shogaols, or paradols, all of which consist of series
with 4, 6, or 8 methylene groups in a side chain of the
molecule [19]. Several of the members of these three groups
of substances inhibit COX-1 and COX-2, as do ibuprofen and
other NSAIDs, and in addition substances from ginger will
inhibit the enzyme 5-lipoxygenase (LOX) [19].
Betamethasone was applied as an aqueous solution of
betamethasone 21-phosphate disodium (Sigma, St. Paul,
MO, USA) with concentration of 1.32mg/mL, equivalent
to betamethasone-base 1.00mg/mL. Ibuprofen (Sigma) was
dissolved in water to a concentration of 1.00mg/mL in
a water bath at 100◦C for five minutes. The fluid ginger
extract EV.77/15 (Ferrosan A/S, Denmark) was made up
to a concentration of 1.00mg/mL by dissolving the extract
in water for five minutes on a boiling water bath for five
minutes during regular shaking. The concentration of the
extract was chosen according to Grzanna et al. [19] and
as recommended by the firm. The three solutions were
added to DMEM medium with 3% FBS, penicillin, and
streptomycin in volumes 1+9, such that the concentration of
betamethasone-base, ibuprofen, or ginger extract 77/15 was
100 μg/mL in the cell culture medium. As control solution
(no treatment), a mixture of sterile water to DMEMmedium
with 3% FBS, penicillin, and streptomycin, 1+9 (volume)
was used. The final media with additions were filtered
through an 0.22 μmmembrane filter.
2.7. Time Course of Cell Experiments. The eight-field plates
were inspected in an inverse microscope after their cells,
following seeding, had been cultured for 2 or 3 days, and
the degree of confluency and the appearance of the cell
layer were recorded. Only fields containing cells with good
fibroblast morphology and not less than 40% confluency
were taken for continuation of the experiment. The used
cell-culture medium was aspirated completely and replaced
with 1.5mL of either DMEM/high glucose reduced serum
with 3% Fetalclone III, diluted 9 parts of the medium
with one part of sterile water for the untreated control
group, or diluted in the same ratio with solutions of
anti-inflammatory substances. The cell plates were then
cultured for 72 hours, inspected as mentioned previously,
and the cell-culture medium was aspirated completely. These
samples of conditioned medium were aliquoted to labelled
cryostorage tubes and stored at −80◦C until analysis. The
cells in the four fields in rows “A” were harvested after
they had been rinsed with 1.0mL phosphate-buﬀered saline
under 2 minutes shaking, detached with phosphate-buﬀered
saline with 0.5mM EDTA, scraped oﬀ with a cell scraper,
transferred almost completely to a microcentrifuge tube, and
pelleted in this for later lysing aiming at analysis of cytosolic
substances.
To the rows “B” of the cell plates were added 1.5mL
of a freshly prepared portion of either DMEM/high glucose
reduced serum with 3% Fetalclone III, diluted 9 : 1 with ster-
ile water or with solutions of anti-inflammatory substances,
and to the rows “C” were added 1.5 mL of the same media
for untreated control or with test substances added, but with
addion of TNF-α 1 nanogram per mL.
2.8. Quantitative Determination of Cytokines and Chemokines.
The concentrations of the following cytokines and chemok-
ines in the samples of conditioned cell culture media
were determined by enzyme-linked immunosorbent assay
(ELISA): chemokine (C-C motif) ligand 2 (CCL2, also
referred to as MCP-1), interleukin-10 (IL-10), and macro-
phage migration inhibitory factor (MIF), or by multiplex-
immunosorbent assay (MIA): granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ),
interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8
(IL-8) also referred to as CXCL8, interleukin-11 (IL-11),
interleukin-12p70 (IL-12p70), interleukin-15 (IL-15), and
interleukin-17 (IL-17). The ELISA or MIA determinations
were performed with capture antibodies, detection anti-
bodies, and recombinant human protein as calibrator
standard, all from R&D Systems, Minneapolis, MN, USA.
The reagents for MIA determinations were prepared in
our own laboratory: capture antibodies were covalently
coupled to fluorescent, carboxylated beads (Luminex,
Austin, TX, USA) as devised [20, 21]. The concentrations
of capture antibodies in the coupling step had been titrated
in numerous experiments. The density of the combined
suspension of these capture antibody beads was adjusted
to the amount intended for each sample, 1500 beads in
a volume of 25 μL. Aliquots of 25 μL each of the media
samples were pipetted to the wells of a microplate and
incubated with the capture antibody beads for 1.5 hours
with agitation, then a solution of the detection antibodies
for all analytes was added, and incubation resumed for 2
hours, the beads were washed twice with phosphate-buﬀered
saline with intervening agitation for 5 minutes, centrifugated
for pelleting of the beads at the bottom of the wells, and
the supernatant was aspirated by a microtiter plate washer.
A solution of streptavidine RPE (Invitrogen, Molecular
Probes, Eugene, OR, USA) for coupling of this fluorochrome
reporter to the detection antibodies was added, the bead
suspension in the microplate wells was incubated for 30
minutes, the beads were washed twice, resuspended in sheath
fluid for flow cytometry, and analyzed on the BD FACSArray
flow cytometer. The data were analyzed by SigmaPlot 11
(Systat Software, San Jose´, CA, USA), using 4-parameter
logistic regression for expression of calibration curves
and then calculation of sample concentrations with these
parameter values and correction for recovery determined in
the same assays.
2.9. Quantitative Determination of Histamine and Hydrox-
yproline. The concentrations of free hydroxyproline and
histamine in the media samples were determined as devised
[22]. Following derivatization of 30 μL-aliquots with 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate, separa-
tion of the sample components was carried out by high
performance liquid chromatography using a Kinetex 2.6 μm
C18 150 × 4.6mm column (Phenomenex, Torrance, CA,
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USA), in an HPLC instrument from Waters (Milford, MA,
USA) with fluorescence monitoring of the column eluate.
The method is intended for amino acid analysis, but
measures histamine as well.
2.10. Statistical Methods. The data on concentrations of
cytokines and chemokines were analyzed in a variance com-
ponent model [23] with cell culture ID as a random compo-
nent and fixed eﬀects of diagnosis, treatment, whether cells
were stimulated with TNF-α, sample location (elbow, finger
or hand, hip, or knee), sample type (synovial fluid or synovial
membrane), and age and sex of patients. The basic model
(given for IL-6) was then
ln
(
IL-6i j
)
= βDiagnosis, Stimulation, Treatment + βSpltype
+ βLocalization + βSex + βAge + β2Age + ηYi + σεi j ,
(1)
where IL-6i j refers to the IL-6 measurement corrected for
cell density. Index “i” refers to cell culture ID 1 to 28 and
index “ j” refers to the row versus column-plate field within
each cell culture, from 1 to 8. Yi refers to the random eﬀect
of cell culture i; hence η measures the degree of variation
between cell cultures, while σ is a measure of the variation
within the individual cell culture. A similar model was
applied to the other cytokines and chemokines studied. The
concentrations of cytokines and chemokines were corrected
for cell density in the eight-field plates of the individual
cell culture through division by the degree of confluence
and transformed with the natural logarithm to stabilize
the variance. To avoid problems with observations of zero,
one was added to all observations before transformation of
the data. The model for each cytokine was then reduced
by means of the maximum-likelihood method through
standard significance testing, and estimates for levels for each
combination of treatment and diagnosis were calculated for
both stimulated and nonstimulated cells. The levels were
estimated through the mean in a log-normal distribution,
taking both mean and variance of the transformed data
into account. Confidence bands were found as the inverse
logarithm of the mean ± 1.96 times the standard deviation
for the transformed variables, thus making the confidence
bands asymmetric. Likelihood ratio tests were evaluated
through the chi-square distribution.
3. Results
In an ideal world we would select cryo-preserved synovio-
cytes representing a balanced proportion between sex and
age of the subjects from whom the cell isolates came. With
the possibilities presented to us, the distribution and age
(mean, SD, range) of the donor subjects were as follows:
OA: males 0, females 12, age (52.2 y, 10.5 y, 33.1–69.1 y); RA:
males 2, females 8, age (48.8 y, 13.8 y, 28.2–64.5 y); HC: males
6, females 0, age (33.3 y, 2.3 y, 30.1–36.4 y). The figures for the
total population were males 8, females 20, age (46.9 y, 12.6 y,
28.2–69.1 y). The deviation of the distributions from equality
is significant, P < 0.00005 as to sex and P < 0.006 as to age,
Table 1: Origin of cells by joint localization and type of specimen
(SF for synovial fluid; SM for synovial membrane).
Localization
Diagnosis group
OA RA HC
Elbow 0 1 (1 SF; 0 SM) 0
Finger or hand 0 3 (2 SF; 1 SM) 0
Hip 3 (0 SF; 3 SM) 2 (0 SF; 2 SM) 0
Knee 9 (5 SF; 4 SM) 4 (3 SF; 1 SM) 6 (0 SF; 6 SM)
Total 12 (5 SF; 7 SM) 10 (6 SF; 4 SM) 6 (0 SF; 6 SM)
reflecting that the potential HC donors in the hospital were
younger sportsmen.
The localization of the source joints and the type of
specimen drawn and cultured, are listed in Table 1.
A summary of the individual compositions of each cell
population transferred to eight-well cell-culture plates, and
used for a substance exposure experiment, is shown in
Table 2.
Only CD90-positive cells, indicating fibroblast-like syn-
ovial cells or activated endothelial cells, constituted a major
proportion. Presence of macrophage-like synovial cells,
labelled with anti-CD14, as not demonstrated, nor were
macrophage-like synovial cells or unstimulated endothelial
cells, labelled with anti-CD31, demonstrated. The results
referring to labelling with anti-CD68 suggested that up to
2% of the cell population may have been macrophage-like
synovial cells.
The degree of confluence was found constant at visual
inspections under the microscope every three days through-
out each experiment.
All cell cultures, irrespective of treatment, produced
hydroxyproline, which again indicated fibroblast-like cells
with their usual production of extracellular substances.
There was no dependence on treatment or stimulation. There
was a nonsignificant trend towards higher production in OA
and RA compared to HC.
Histamin production was measured in all cell cultures
but showed no dependence on diagnosis, stimulation, or
treatment.
The statistical analysis of the concentrations of cytokines
and chemokines revealed no significant triple interaction
between diagnosis, stimulation, or no stimulation with TNF-
α, and drug treatment for any of the cytokines/chemokines
measured, and no eﬀect of sample type, localization, sex, or
age. Treatment did not interact with diagnosis or stimula-
tion; hence the final model was
ln
(
IL-6i j
)
= βDiagnosis, Stimulation + βT + ηYi + σεi j . (2)
The final model for the other cytokines and chemokines
studied as found to be equivalent.
The dual-interaction between diagnosis and TNF-α
stimulation was significant as to IL-1β (P = 0.02), IL-6
(P = 0.03), and IL-8 (P < 0.0001).
Fibroblast-like synovial cells in vitro in our experiments
secreted an increased amount of the pro-inflammatory
cytokines IL-1β, IL-6, and IL-8 in response to stimulation
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Table 2: Summary of percentages of cells stained positive with specific antibody to binding site, or nonspecific isotype control, for all 28 cell
populations used.
Mean percentage of all 28 cell populations Minimum Maximum
Specific CD Isotype control Specific CD Isotype control Specific CD Isotype control
CD14+ (macrophage-like
synoviocytes)
0.15 0.21 0.00 0.10 0.60 0.30
CD31+ (endothelial cells and
macrophage-like synoviocytes)
0.08 0.26 0.00 0.20 0.40 0.60
CD68+ (macrophage-like
synoviocytes after intracell
staining)
0.56 0.30 0.00 0.20 3.60 1.20
CD90+ (fibroblast-like
synoviocytes)
52.19 0.79 5.00 0.00 98.00 2.00
Table 3: Mean and confidence interval for IL-6 production in
cells unstimulated and stimulated with TNF-α. Concentrations in
pg/mL.
Diagnose OA Diagnose RA Diagnose N
Betamethasone
Not stimulated
25.61
(13.37; 49.02)
16.30
(8.08; 32.86)
19.22
(7.98; 46.32)
Betamethasone
Stimulated
32.04
(16.74; 61.34)
48.36
(23.89; 98.07)
44.94
(18.65; 108.27)
Ibuprofen
Not stimulated
71.13
(37.18; 136.08)
45.27
(22.46; 91.23)
53.40
(22.18; 128.59)
Ibuprofen
Stimulated
89.01
(46.53; 170.29)
134.34
(66.55; 271.22)
124.84
(51.84; 300.61)
Control
Not stimulated
75.98
(39.72; 145.37)
48.36
(23.99; 97.46)
57.05
(23.69; 137.37)
Control
Stimulated
95.09
(49.70; 181.91)
143.5
(71.08; 289.73)
133.36
(55.38; 321.12)
Ginger Extract
Not stimulated
36.05
(18.85; 68.98)
22.94
(11.38; 46.24)
27.07
(11.24; 65.18)
Ginger Extract
Stimulated
45.12
(23.58; 86.32)
68.10
(33.73; 137.48)
63.28
(26.28; 152.37)
with TNF-α, both untreated and when treated with anti-
inflammatory substances. This was the case with cells orig-
inating from either OA, RA, or HC individuals, as illustrated
for IL-8 in Figure 1.
The concentrations of IL-6 in the conditioned media
from nonstimulated and stimulated cells at the diﬀerent
diagnoses and treatments are shown in Table 3.
Unstimulated OA cells showed a higher IL-6 production
than unstimulated RA and HC cells, which showed a similar
IL-6 production. TNF-α stimulation caused less increase in
IL-6 production in OA cells than in RA or HC cells, which
showed similar responses to TNF-α stimulation.
Likewise, IL-8 production was higher in un-stimulated
cells from OA patients than in cells from RA or HC subjects.
Following TNF-α stimulation, the IL-8 production, and
thereby measured IL-8 concentration, was increased to a
similar level irrespective of diagnosis group.
Un-stimulated OA-cells did not diﬀer from un-stimulat-
ed RA and HC cells concerning IL-1β production. However,
following TNF-α stimulation, IL-1β production increased for
Diagnosis
OA RA HC
IL-8, control treatment
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104
Figure 1: IL-8 production, given in log pg/mL, in cells fromOA, RA
and HC without stimulation (light columns) and following TNF-α
stimulation (dark columns).
all cells measured, but a higher increase in IL-1β production
was seen in RA cells than in OA cells, which both presented a
higher increase than HC cells.
IL-11, IL-12p70, IL-15, and IL-17 were measured in
variable, low concentrations, with several cultures not
exceeding the lower level of detection, indicating a general
low production of these cytokines and no response in
expression of these to TNF-α stimulation. CCL2 showed
a high increase in production after TNF-α stimulation,
but this was not significant in the statistical analysis due
to a large variation between individual cell cultures. MIF
concentrations were relatively high, around 500 pg/mL, and
did not change with TNF-α stimulation.
When looking at response to the anti-inflammatory
drugs, illustrated for IL-8 in Figures 2(a)–2(c) and for IL-6,
Table 3, ibuprofen showed no eﬀect, while the ginger extract
and betamethasone were both eﬀective and showed a similar
reduction of cytokine production. This is also seen from the
P values when comparing the diﬀerent treatments, shown in
Table 4.
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Figure 2: IL-8 production, given in log pg/mL, in cells from HC (a), OA (b), and RA (c), unstimulated (light columns) and stimulated with
TNF-α (dark columns), when exposed to betamethasone, ibuprofen, no treatment (control), or ginger extract treatment.
4. Discussion
Overall, our study shows that the cell model developed
here may be a useful in vitro model, both in diﬀerentiating
between OA and RA, and when testing the eﬀectiveness of
various anti-inflammatory drug substances.
The cell cultures determined to be fibroblast-like syn-
oviocytes were well functioning [24] indicated by their
hydroxyproline production throughout the study, as well as
by the constant degree of confluence.
Histamine production was found not to be influenced by
diagnosis, stimulation, or treatment. This indicates that self-
produced histamine was not part of the cell culture’s response
to stimulation. This behaviour is in line with what is expected
from a synoviocyte population [25].
Early diagnosis of RA in cases not yet fulfilling the ACR
criteria [11] may benefit from looking at diﬀerences in IL-
6 production from fibroblast-like synoviocyte cell cultures.
Since no subject-related dependent variables like age were
included in the statistical model, it may be possible to
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Table 4: P values for the comparison of the diﬀerent treatments on
IL-6 an IL-8 production.
IL-6 production IL-8 production
Control versus betamethasone <0.0001 <0.0001
Control versus ibuprofen 0.74 0.42
Control versus ginger extract 0.0003 0.0004
Betamethasone versus
ibuprofen
<0.0001 0.0005
Betamethasone versus ginger
extract
0.10 0.46
Ibuprofen versus ginger 0.0003 0.006
provide a method for distinguishing the cytokine reactions
of fibroblast-like synoviocytes isolated from subjects from
these groups. A larger cell material from a population of
OA and RA patients must though be measured to document
that the diﬀerence seen in our study is a general diﬀerence
between cells from these two populations. The fact that the
cells in our study came from diﬀerent joints speaks, on the
other hand, for that the fibroblast-like synovial cells studied
here have some general features when they respond to TNF-
α and that OA and RA cells show some real diﬀerences here.
Our healthy controls had no prehistory of arthritic disease
and came to the clinic due to physical trauma or overuse.
They showed no sign of inflammatory disease or sign of
arthritis in any form. The healthy control fibroblasts in our
study must therefore be considered as a good representation
of cells from a healthy joint. As with the OA and RA cells,
a higher number of subjects would have strengthened the
data, but getting permission to take these samples is not
easy, and the number in the study is high enough for the
statistical methods applied. Overall, our results based on
the cell populations studied must be considered reliable,
although one must be careful in generalising the results, until
more studies are carried out.
The striking eﬀect of the ginger extract on secretion of
proinflammatory cytokines, showing as good an eﬀect as
betamethasone in reducing production of these cytokines,
is a novel finding which may lead to reconsideration of the
eﬀect of ginger extract as a possible drug in arthritis therapy.
The eﬀect on inhibition of TNF-α production by the ginger
extract was earlier reported in synoviocytes by Frondoza et
al. [26] and Phan et al. [27], and ginger is known to have
a moderate eﬀect on osteoarthritis in vivo [28, 29]. Funk et
al. [30] also found a promising eﬀect of ginger extract in
experimental arthritis in rats. Our results are in accordance
with these earlier studies and suggest an eﬀect of ginger
on inflammatory processes at cell level. Furthermore, we
show that ginger in the form of a mixture of substances
from both Zingiber oﬃcinale and Alpinia galanga, as applied
in our model, is as eﬀective an anti-inflammatory drug as
Betamethasone in the population of RA-derived fibroblasts.
Use of ginger as an anti-inflammatory could be suggested
as a supplement to the anti-inflammatory drugs applied in
RA treatment, but clinical studies are needed to support if
the results in our study are paralleled to an eﬀect in vivo.
That ibuprofen in the same situation shows close to no
eﬀect on our cells can only be interpreted as ibuprofen’s
eﬀect must take place at another level of the inflammatory
processes, since the solutions applied were made up on a
day to day basis, and a dependence on only one batch with
an ineﬀective drug, causing the seen result, could be ruled
out. Another interpretation could have been that ibuprofen
was applied at too low a concentration. The concentration
applied was though as high as it was possible in terms of
solubility in aqueous media, ten times lower than saturated.
In vivo, ibuprofen concentrations in blood are expected
to have a substantial eﬀect on pain from 11 to 40 μg/mL
[31, 32]. In our study, the ibuprofen concentration in the cell
medium was 100 μg/mL; that is, the applied concentration
was in excess of the eﬀective plasma concentration in vivo.
The lack of an eﬀect of ibuprofen can therefore not be due
to an ineﬃcient batch of the drug or applying a too low
concentration for an eﬀect of the drug.
5. Conclusions
In conclusion, ginger extract EV77/15 is as eﬀective an
anti-inflammatory agent as betamethasone in this in vitro
cell model of cultured fibroblast-like synoviocytes. Looking
at the cytokine response from TNF-α stimulated, cultured
fibroblast-like synoviocytes, isolated from subjects with OA
or RA patients, promise to be a useful pharmacological
model, but clinical studies to support results from such a
model are needed.
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